Edition:
India

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

106.50EUR
15 Dec 2017
Change (% chg)

€1.40 (+1.33%)
Prev Close
€105.10
Open
€104.90
Day's High
€106.50
Day's Low
€104.70
Volume
6,184,479
Avg. Vol
1,904,322
52-wk High
€123.90
52-wk Low
€96.18

Chart for

About

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology. The... (more)

Overall

Beta: 0.98
Market Cap(Mil.): €96,918.28
Shares Outstanding(Mil.): 826.95
Dividend: 2.70
Yield (%): 2.30

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Nektar Therapeutics Says Received Notice Of Termination From Bayer Of Co-Development, License, Co-Promotion Agreement

* NEKTAR THERAPEUTICS - ‍ON DEC 14, CO RECEIVED NOTICE OF TERMINATION FROM BAYER OF CO-DEVELOPMENT, LICENSE,CO-PROMOTION AGREEMENT, DATED AUG 1, 2007​ Source text: (http://bit.ly/2BsgSdG) Further company coverage:

15 Dec 2017

BRIEF-Bayer's Rivaroxaban Submitted To U.S. FDA For Approval

* RIVAROXABAN SUBMITTED TO U.S. FDA FOR APPROVAL IN PATIENTS WITH CORONARY AND/OR PERIPHERAL ARTERY DISEASE Source text - http://bit.ly/2B4uKdl Further company coverage: (Gdynia Newsroom)

11 Dec 2017

EU regulators to warn Bayer about Monsanto bid: source

BRUSSELS EU antitrust regulators are set to warn Bayer its planned purchase of U.S. seed maker Monsanto may hurt competition, a person familiar with the matter said on Friday, a move that would force Bayer to offer concessions to address the concerns.

09 Dec 2017

EU regulators to warn Bayer about Monsanto bid -source

BRUSSELS EU antitrust regulators are set to warn Bayer its planned purchase of U.S. seed maker Monsanto may hurt competition, a person familiar with the matter said on Friday, a move that would force Bayer to offer concessions to address the concerns.

09 Dec 2017

UPDATE 2-EU regulators to warn Bayer about Monsanto bid -source

BRUSSELS, Dec 8 EU antitrust regulators are set to warn Bayer its planned purchase of U.S. seed maker Monsanto may hurt competition, a person familiar with the matter said on Friday, a move that would force Bayer to offer concessions to address the concerns.

09 Dec 2017

EU regulators to warn Bayer about Monsanto bid - source

BRUSSELS, Dec 8 EU antitrust regulators are expected to warn Bayer in the coming weeks that its planned takeover of U.S. seed maker Monsanto may hurt competition, a person familiar with the matter said on Friday.

08 Dec 2017

Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuit

A Philadelphia state court jury on Tuesday ordered Bayer AG and Johnson & Johnson to pay $27.8 million to an Indiana couple over the drugmakers' failure to warn of internal bleeding risks from their blood thinner Xarelto.

06 Dec 2017

UPDATE 1-Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuit

Dec 5 A Philadelphia state court jury on Tuesday ordered Bayer AG and Johnson & Johnson to pay $27.8 million to an Indiana couple over the drugmakers' failure to warn of internal bleeding risks from their blood thinner Xarelto.

06 Dec 2017

CORRECTED-Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuit

Dec 5 A Philadelphia state court jury on Tuesday ordered Bayer AG and Johnson & Johnson to pay $27.8 million to an Indiana couple over the drugmakers' failure to warn of internal bleeding risks by its blockbuster drug Xarelto.

06 Dec 2017

BRIEF-Bayer: Updated Clinical Data From Larotrectinib Pediatric Phase I SCOUT Trial

* ‍UPDATED LAROTRECTINIB PEDIATRIC CLINICAL TRIAL DATA DEMONSTRATE CONTINUED DURABILITY OF RESPONSE IN TRK FUSION CANCERS​ Source text for Eikon: [ID:http://bit.ly/2iJSOeQ] Further company coverage: (Gdynia Newsroom)

04 Dec 2017

Earnings vs. Estimates